Meijerink J P, Goverde G J, Smetsers T F, Raemaekers J M, Bogman M J, de Witte T, Mensink E J
Department of Medicine, University Hospital St. Radboud Nijmegen, The Netherlands.
Ann Oncol. 1994;5 Suppl 1:43-5. doi: 10.1093/annonc/5.suppl_1.s43.
A competitive PCR method was developed, enabling accurate quantitation of residual lymphoma cells carrying the t(14;18) in blood and bone marrow samples of follicular non-Hodgkin's lymphoma (NHL) patients during treatment.
A patient with residual lymphoma cells received an allogeneic bone marrow transplantation (BMT). Since BMT, the patient has been in continuing clinical complete remission.
Using the competitive PCR and two-step PCR method, we were able to demonstrate a gradual decline in the number of lymphoma cells within consecutive patient blood and bone marrow samples after BMT.
The competitive PCR is a suitable method for the detection of minimal residual disease. Further research might reveal the clinical relevance of data obtained by this method.
开发了一种竞争性聚合酶链反应（PCR）方法，可在滤泡性非霍奇金淋巴瘤（NHL）患者治疗期间，对其血液和骨髓样本中携带t(14;18)的残留淋巴瘤细胞进行准确定量。
一名携带残留淋巴瘤细胞的患者接受了异基因骨髓移植（BMT）。自BMT以来，该患者一直处于持续临床完全缓解状态。
使用竞争性PCR和两步PCR方法，我们能够证明BMT后连续的患者血液和骨髓样本中淋巴瘤细胞数量逐渐下降。
竞争性PCR是检测微小残留病的合适方法。进一步研究可能会揭示通过该方法获得的数据的临床相关性。
